Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: Results from INSPIRE ME IAA

Diabetes, Obesity and Metabolism

Volumn 15, Issue 7, 2013, Pages 629-641

  Smith, J ^a   Nazare, J A ^a   Borel, A L ^b   Aschner, P ^c   Barter, P J ^d   Van Gaal, L ^e   Matsuzawa, Y ^f   Kadowaki, T ^g   Ross, R ^h   Brulle Wohlhueter, C ⁱ   Almeras N ^a   Haffner, S M ^j   Balkau, B ^k   Despres J P ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIV GRENOBLE ALPES   (France)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d HEART RESEARCH INSTITUTE   (Australia)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f SUMITOMO HOSPITAL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ SANOFI   (France)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k INSERM   (France)

more..

Author keywords

Adipose tissue; Body composition; Liver; Observational study; Type 2 diabetes treatment

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY COMPOSITION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; FEMALE; HUMAN; INTRAABDOMINAL FAT; LIPID LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PREVALENCE; RISK ASSESSMENT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84878923995     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12075     Document Type: Article

References (33)

1. Patlak M. New weapons to combat an ancient disease: treating diabetes. FASEB J 2002; 16: 1853.
2. CDC. Diabetes Data & Trends. Atlanta: Department of Health and Human Services. Cetners for Disease Control and Prevention, 2011.
3. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
4. American Diabetes Association. Standards of medical care in diabetes. 2012. Diabetes Care 2012; 35(Suppl. 1): S11-63.
5. Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S1-S201.
6. WHO/IDF. Diabetes action now: an initiative of the World Health Organization and the International Diabetes Federation. In: WHOID, ed. Federation. Geneva: World Health Organization, 2004.
7. Smith JD, Borel AL, Nazare JA et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA Study. J Clin Endocrinol Metab 2012; 97: 1517-1525.
8. van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993; 17: 187-196.
9. Sjostrom L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol 1986; 250: E736-745.
10. Despres JP, Prud'homme D, Pouliot MC, Tremblay A, Bouchard C. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. Am J Clin Nutr. 1991; 54: 471-477.
11. Ferland M, Despres JP, Tremblay A et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989; 61: 139-148.
12. Shores NJ, Link K, Fernandez A et al. Non-contrasted computed tomography for the accurate measurement of liver steatosis in obese patients. Dig Dis Sci 2011; 56: 2145-2151.
13. Davidson LE, Kuk JL, Church TS, Ross R. Protocol for measurement of liver fat by computed tomography. J Appl Physiol 2006; 100: 864-868.
14. Borel AL, Nazare JA, Smith J et al. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity. Metabolism 2012; 61: 262-272.
15. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56.
16. Foy CG, Hsu FC, Haffner SM et al. Visceral fat and prevalence of hypertension among African Americans and Hispanic Americans: findings from the IRAS family study. Am J Hypertens 2008; 21: 910-916.
17. Gastaldelli A, Kozakova M, Hojlund K et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544.
18. Hanley AJ, Wagenknecht LE, Norris JM et al. Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family study. Diabetologia 2009; 52: 2079-2086.
19. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
21. Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011; 28: 1343-1351.
22. Yan AT, Yan RT, Tan M et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119: 676-683.
23. Liberopoulos E, Vlasserou F, Mitrogianni Z, Papageorgantas I, Elisaf M. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology 2012; 63: 184-193.
24. Sam S, Haffner S, Davidson MH et al. Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes 2008; 57: 2022-2027.
25. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-459.
26. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799-2810.
27. Putnam W, Lawson B, Buhariwalla F et al. Hypertension and type 2 diabetes: what family physicians can do to improve control of blood pressure-an observational study. BMC Fam Pract 2011; 12: 86.
28. Kang AY, Park SK, Park SY et al. Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management. Diabetes Metab J 2011; 35: 264-272.
29. Kuznik A, Mardekian J. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol 2011; 10: 31.
30. Belletti DA, Zacker C, Wogen J. Hypertension treatment and control among 28 physician practices across the United States: results of the Hypertension: Assessment of Treatment to Target (HATT) Study. J Clin Hypertens (Greenwich) 2010; 12: 603-612.
31. Francis GA. The complexity of HDL. Biochim Biophys Acta 2010; 1801: 1286-1293.
32. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011; 13: 544-552.
33. McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011; 71: 1917-1946.